Lysogene (LYS.PA) Fundamental Analysis & Valuation

EPA:LYS • FR0013233475

Current stock price

0.2795 EUR
0 (-0.71%)
Last:

This LYS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LYS.PA Profitability Analysis

1.1 Basic Checks

  • In the past year LYS has reported negative net income.
  • LYS had a negative operating cash flow in the past year.
LYS.PA Yearly Net Income VS EBIT VS OCF VS FCFLYS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M -10M -15M

1.2 Ratios

  • LYS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LYS.PA Yearly ROA, ROE, ROICLYS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 100 -100 200 300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LYS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYS.PA Yearly Profit, Operating, Gross MarginsLYS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. LYS.PA Health Analysis

2.1 Basic Checks

  • LYS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LYS has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for LYS is higher compared to a year ago.
LYS.PA Yearly Shares OutstandingLYS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M
LYS.PA Yearly Total Debt VS Total AssetsLYS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 10M 20M 30M

2.2 Solvency

  • LYS has an Altman-Z score of -3.85. This is a bad value and indicates that LYS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LYS (-3.85) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.85
ROIC/WACCN/A
WACC7.45%
LYS.PA Yearly LT Debt VS Equity VS FCFLYS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M 10M -10M

2.3 Liquidity

  • LYS has a Current Ratio of 2.14. This indicates that LYS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.14, LYS is in line with its industry, outperforming 46.91% of the companies in the same industry.
  • A Quick Ratio of 2.14 indicates that LYS has no problem at all paying its short term obligations.
  • The Quick ratio of LYS (2.14) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 2.14
LYS.PA Yearly Current Assets VS Current LiabilitesLYS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LYS.PA Growth Analysis

3.1 Past

  • The earnings per share for LYS have decreased strongly by -150.29% in the last year.
  • The Revenue for LYS has decreased by -72.09% in the past year. This is quite bad
  • LYS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.29% yearly.
EPS 1Y (TTM)-150.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.28%
Revenue 1Y (TTM)-72.09%
Revenue growth 3Y1.29%
Revenue growth 5YN/A
Sales Q2Q%188.81%

3.2 Future

  • The Earnings Per Share is expected to decrease by -5.25% on average over the next years.
  • The Revenue is expected to decrease by -22.24% on average over the next years. This is quite bad
EPS Next Y-37.04%
EPS Next 2Y-28.62%
EPS Next 3Y-21.98%
EPS Next 5Y-5.25%
Revenue Next Year-50%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.24%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LYS.PA Yearly Revenue VS EstimatesLYS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
LYS.PA Yearly EPS VS EstimatesLYS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. LYS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LYS. In the last year negative earnings were reported.
  • Also next year LYS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYS.PA Price Earnings VS Forward Price EarningsLYS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYS.PA Per share dataLYS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as LYS's earnings are expected to decrease with -21.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.62%
EPS Next 3Y-21.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LYS.PA Dividend Analysis

5.1 Amount

  • LYS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LYS.PA Fundamentals: All Metrics, Ratios and Statistics

Lysogene

EPA:LYS (1/5/2023, 7:00:00 PM)

0.2795

0 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.97M
Revenue(TTM)3.73M
Net Income(TTM)-13.61M
Analysts45.71
Price Target11.22 (3914.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)88.03%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.21
BVpS-0.16
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 2.14
Altman-Z -3.85
F-Score2
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)74.03%
Cap/Depr(5y)81.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.28%
EPS Next Y-37.04%
EPS Next 2Y-28.62%
EPS Next 3Y-21.98%
EPS Next 5Y-5.25%
Revenue 1Y (TTM)-72.09%
Revenue growth 3Y1.29%
Revenue growth 5YN/A
Sales Q2Q%188.81%
Revenue Next Year-50%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.24%
EBIT growth 1Y-161.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.57%
EBIT Next 3Y-19.68%
EBIT Next 5Y-7.11%
FCF growth 1Y23.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.15%
OCF growth 3YN/A
OCF growth 5YN/A

Lysogene / LYS.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Lysogene (LYS.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to LYS.PA.


What is the valuation status of Lysogene (LYS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to Lysogene (LYS.PA). This can be considered as Overvalued.


How profitable is Lysogene (LYS.PA) stock?

Lysogene (LYS.PA) has a profitability rating of 0 / 10.